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Abstract In its ﬁrst 25 years JCAMD has been dissemi-
nating a large number of techniques aimed at ﬁnding better
medicines faster. These include genetic algorithms, COM-
FA, QSAR, structure based techniques, homology model-
ling, high throughput screening, combichem, and dozens
more that were a hype in their time and that now are just a
useful addition to the drug-designers toolbox. Despite mas-
sive efforts throughout academic and industrial drug design
research departments, the number of FDA-approved new
molecularentitiesperyearstagnates,andthepharmaceutical
industry is reorganising accordingly. The recent spate of
industrial consolidations and the concomitant move towards
outsourcing of research activities requires better integration
of all activities along the chain from bench to bedside. The
next25 yearswillundoubtedlyshowaseriesoftranslational
science activities that are aimed at a better communication
between all parties involved, from quantum chemistry to
bedside and from academia to industry. This will above all
include understanding the underlying biological problem
and optimal use of all available data.
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Introduction
Life expectancy of man, and especially man in the western
world, increased by more than 2 days per week for the
whole previous century [1]. Much of this dramatic increase
is to the credit of hygiene, but medicines, and especially
antibiotics and vaccines, have contributed signiﬁcantly too.
In the ﬁrst world war, for example, almost as many soldiers
died of disease as of bullets [2]. During the second world
war this unfortunate situation got ‘remedied’ by the intro-
duction of sulphonamides and penicillin [3].
At this moment medical doctors around the world can
write prescriptions for tens of thousands of medicines [4],
and an even larger number is available of herbal medicines,
homeopathic wonder-cures, and other preparations for
which the medicinal value has not been proven [5]. Most
medicines function by interacting with proteins in the body.
Of the more than twenty thousand protein types in our body
less than ﬁve hundred are targeted by all these medicines
[6]. This, of course, gives hope for the future of drug design
because most proteins are still available as a target for
which a blockbuster drug can be designed.
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molecular entities (NMEs) that the FDA approves per year
for use as medicines certainly isn’t growing [7], while the
amount of money involved goes up much faster than
inﬂation [7] even when we include Obama’s Troubled
Asset Relief Program [8].
This journal (JCAMD) has published many, many arti-
cles on techniques that according to the authors of these
articles were the holy grail for drug design, and that in
today’s reality are just good tools used in this process.
Following a path familiar in science, someone has a good
idea, gives it a name and publishes it. Others follow suit
and publish improvement after improvement, after which
yet others start testing all similar methods. An example is
the use of support vector machines for ligand selection.
This was introduced in 2000 [10] and only 3 years of
improvements were needed before the ﬁrst comparison
methods were published [11]. Figure 1 illustrates the des-
peration of pharmaceutical industries. The ever increasing
costs mainly result from development and marketing [12]
and, unfortunately for us, not from research. This might
explain why each time a new drug design research tool gets
published pharmaceutical industries immediately jump on
it and give it a hype status.
A brief history of tools
The ﬁrst hype in drug design was born out of the famous
article by Hol [13] in which he coined the name ‘rational
drug design’ for all protein-structure based techniques,
thereby implicitly calling all methods that actually worked,
such as screening or luck, irrational; see Fig. 2.
It is not by eye that we can determine either the ﬁtness
of a ligand for a pocket, or the safety or efﬁcacy of a drug.
It does not seem illogical to assume that the founders of
JCAMD were at least subconsciously dealing with the
oversimpliﬁcation implied by Fig. 2 when they started this
journal. And we believe that most articles published in
JCAMD have dealt with aspects of drug design ‘left out’ of
Fig. 2. The advent of faster computers like ﬁrst the VAX/
VMS, then supercomputers such as the CRAY, and ﬁnally
the PC, have allowed scientist to numerically solve
chemical problems of ever increasing size and complexity.
Semi-empirical quantum calculation methods have been
devised to calculate the chemically relevant aspects of the
electronic wave-functions associated with small organic
molecules and thus compute their 3D dimensional struc-
tures as well as the energy of their conformers [15–19]. All
the techniques derived in this domain are referred to as
ligand-based drug design. In parallel, the development of
molecular mechanics force ﬁelds combined with the fact
that Newton’s equations of motion could be solved for
entire proteins in their aqueous environments were true
innovations in the investigation of the structure function
relationships [20–28]. Thus, not only the geometry and the
potential energy surface of macromolecular assemblies
could be calculated but also their dynamic and thermody-
namic properties [29, 30]. For the early computational
chemists this opened the perspective of testing at will the
energy of interactions between protein targets and large
collections of small molecule ligands [29, 31, 32]. The
original thoughts that this would replace experimental
validation processes, though, have long been shown to be a
nice dream at best. The perception that the underlying
Fig. 1 Amount of money spent in billion US$/NME (after Munos
[7]). Munos summarises these numbers eloquently in his 2009 review,
but you are also encouraged to read the commentary by Firestone [9]
Fig. 2 Methotrexate in the active site pocket of dihydrofolate
reductase (PDBid:4DFR [14]). Next to a monochrome picture
showing this same ﬁt, Hol wrote: ‘‘As to whether a drug can actually
reach its target, e.g. the active center of an enzyme, is primarily a
spatial problem. Assuming that the structures of both components are
known, computer graphics can help in checking the suitability of a
potentially active substance. As example, the structure of the complex
formed between a bacterial dihydrofolate-reductase, NADP and the
anticancer drug methotrexate (gray dots) is shown on the right.A s
one can see, it ﬁts’’ [13]
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123mechanism of protein–ligand recognition would be
unravelled and would thus allow what ever since has been
called structure-based drug design has never looked so
clear and promising as at that particular moment in 1986.
With the exception of a very small fraction of ligands
that are purely rigid, most bioactive ligands have a number
of rotatable bonds that make them ﬂexible. The values of
the torsion angles in ligands are determined by the valence
electrons of the atoms. The development of empirical
molecular mechanics force ﬁeld in the late 1970s [33, 34]
have allowed for the in silico determination of the geom-
etries (low energy conformers) of ligands in vacuo.
Application of these methods relies on two underlying
assumptions: (1) that the conformation of the dissolved
ligand corresponds closely to its gas-phase conformation
[35]; and (2) that the biologically active conformation of
the ligand is likely to be found among the set of low energy
conformers of the isolated ligand [36, 37]. The combined
knowledge of the ligand structure (determined by NMR or
X-ray), the measured binding afﬁnities, and the spatial
overlay of the low energy conformations should then be
sufﬁcient to establish a structure activity relationship [38]
and pinpoint the spatial organization of the recurrent
chemical features correlated with activity (pharmaco-
phore). This paved the way for a series of successes for
ligand-based drug design [e.g. 39, 40, 16]. However,
although it seems fairly reasonable at ﬁrst sight, both
assumptions in practice proved to be incomplete and/or
insufﬁcient [41–50].
The computational process by which the complementary
aspects between a ligand and a receptor binding site can be
ascertained has been explored with the design of speciﬁ-
cally dedicated docking programmes. Early docking
methods were based uniquely on assessing the shape
complementarity [51] between a pocket in the 3D structure
of a protein and low energy conformers of a ligand. The
approach was computationally cumbersome due to the
need to systematically search all possible ligand orienta-
tions within the pocket and scoring each of these poses by
its steric hindrance. Subsequent developments have taken
place in several directions: improved scoring functions
[52–63] different ways to deal with ligand ﬂexibility [60,
64–72], and most recently also ways to deal with receptor
ﬂexibility [73–78]. Fundamental research has been per-
formed into directions such as desolvation energies
[79–83], or other aspects of the force ﬁelds used for scoring
docking poses [66, 78, 84–96].
The idea to calculate from ﬁrst principles all atomic
motions occurring in an active enzyme in its aqueous
environment has attracted many scientists to computer
aided molecular design. Starting with the atomic loci
obtained from the X-ray structure of en enzyme it can be
envisaged to integrate Newton’s equations [29, 31]. A
series of snapshots describing the trajectory of the enzyme
over time could thus be produced and ensemble average
properties calculated based on Boltzmann’s ergodic
hypothesis. The near inﬁnite computer time needed for
such experiments muted this ﬁeld till concepts from
alchemy could be embraced. In silico, one is not bound by
the sequential order of events that govern paths between
states, and hence so-called thermodynamic cycle methods
could be developed that replaced chemical steps with
alchemical steps that in principle should lead to the same
outcome [29, 30, 97, 98].
Comparative Molecular Field Analysis (CoMFA) is
based on the overlay of active ligands [99, 100–102]. Ini-
tially, the technique was more a concept than an effective
tool as computer power was very limited and molecular
descriptors as well as dedicated algorithms needed to be
developed [103]. The underlying idea that the 3D dimen-
sional steric/non-bonded (Van der Waals) and electrostatic
potential ﬁelds generated by the spatial organization of the
chemical features around the scaffold of a ligand (Fig. 3)
play a fundamental role in the biomolecular receptor rec-
ognition was so intuitively right and the technique made a
break-through in 1988 [99]. Examples of the application of
the method are plentiful [100]. About 15% of all articles in
JCAMD refer to the use of this technique, reﬁned and
applied in all sorts of ways to produce the overly famous
quantitative structure activity relationship (QSAR) equa-
tions. However, CoMFA suffers from three drawbacks: (1)
the alignment of the ligands in the pocket must be either
known or gambled correctly; (2) the method has been
established for rigid or quasi-rigid classes of molecules
(e.g. steroids); and (3) the detailed inﬂuence of the protein
pocket is not known which means that any feature that is
not implicitly present in the training set will be missed
[104–109]. These nearly fatal drawbacks prevented the
generalization of the method as a standalone solution to
rational drug design. Certainly, the best way to apply
CoMFA is to combine it with a pharmacophore model and
a carefully conducted conformational study of the ligands
[110].
Many drug design projects include at some stage
knowledge of the 3D structure of the target protein, and
homology modelling is normally used when neither X-ray
nor NMR derived coordinates are available [111–118].
Many computer programs were written for this purpose
[119–123] and the CASP competition [124] illustrates
every 2 years where the ﬁeld stands. Presently, YASARA
seems to be performing very well [122], but many labs are
working hard so this situation might change again in the
future. For example, methods are under development that
use PLIM [125] to provide a ﬁrst ﬁx on the ligand docking
site where-after steered Molecular Dynamics is used to
continue the trajectory to convergence.
J Comput Aided Mol Des (2012) 26:137–150 139
123Similar to the CASP competitions, the GPCR-DOCK
[126, 127] competitions have evaluated the quality of
docking software, but with the additional complexity that
the target structures needed to be modelled before docking
could be attempted. In recent years a whole series of
studies have been published in which homology modelling,
combined with other tools, proved a viable replacement for
the cumbersome experimental determination of target
structures [111, 114, 128, 129]. The good performance of
two Dutch teams [130] in the recent GPCR Dock compe-
tition [127] beautifully illustrates the often mentioned fact
that even the best tools only perform well in the hands of
good scientists [131]. In this latter article we ﬁnd the
interesting quote ‘‘Interestingly enough, it is the model
built with most human intervention which proves to be the
best’’.
In the early 1990s the radical new idea emerged that
instead of the virtual and/or real screening of large libraries
of already existing molecules to identify new bioactive
hits, one could rather attempt to construct entirely new
synthesizable molecular entities solely based on the
knowledge of the active site of the pharmaceutical target
enzyme. [132–134]. To do so, small organic fragments
composed of few atoms only must be assembled in silico
inside the binding sites of enzymes in such a way that
optimal protein–ligand, steric, and electronic complemen-
tarity is achieved [84, 125, 135–141]. The major problem
of this approach arises from the complexity of the active
site landscape and the combinatorial vastness of all
possible arrangements of fragments in the volume delin-
eated by an enzyme active site [66, 142–144]. How to
choose the ﬁrst fragment and where should it be positioned
and oriented with respect to the inner surface of the binding
pocket or cleft [143, 145, 146]? Which next fragment
should be attached to it? [147]? The genetic algorithms [66,
142, 148–150] have been invented which allow this con-
cept to be realized within a tractable amount of computer
time by performing random transformations on a ligand
collection. These transformations are selection, mutation,
and crossover, and are reminiscent of the corresponding
evolutionary processes in biology underlying the optimi-
sation of genes, hence their name ‘genetic algorithms’.
Experience shows that these algorithms provide solutions
that nicely ﬁt the objective function, although it often is
difﬁcult to understand exactly why [66].
Randomly screening very large libraries containing up
to 10
5 or even 10
6 chemical entities in in vitro enzymatic
assays to produce leads has been the central paradigm of
the pharmaceutical industry across the 1990s. However,
after years of operating very expensive screening facilities,
it has been realized that the hits produced were not of the
expected quality. For example, often a bias is observed
toward too lipophilic compounds that are impossible to
optimize. Compared to the actual number of chemically
entities (*inﬁnite) the any amount of compounds that can
be screened via this process is essentially zero [151, 152].
In parallel, computational chemists had inferred that
screening could be successfully operated virtually
throughout computers at all stages in the drug design
process from hit identiﬁcation via hit optimization to lead
optimization [153–162]. In each of these three stages vir-
tual libraries can be created and ﬁltered either using
chemometrics to exclude molecules that obviously aren’t
drug-like because of their predicted solubility or ADME/
Tox properties, or using 3D chemical molecular descriptors
(pharmacophores), or using docking results. Thus, libraries
of compound that do not actually exist can be screened and
a much smaller, manageable number of compounds
selected. This is of particular advantage at the stage of lead
optimization, when only few compounds are left. Scaffolds
of lead compounds usually carry a number of branching
points were chemical variation is allowed. The in silico
creation of combinatorial libraries of all the variant com-
pounds is a dramatically faster process than its in vitro
counterpart [163–165].
One of the main difﬁculties in establishing reliable and/
or transferrable QSAR equations is that, even within a class
of chemical analogues, ligand afﬁnities may not respond
linearly to the variation of one or several of the molecular
descriptors that have been identiﬁed as related to activity.
For instance, across a series of chemical substituents sorted
by increasing polarity the measured afﬁnity may respond
Fig. 3 Contour representation of key features from a CoMFA
analysis of a series of coumarin substrates and inhibitors of
cytochrome P4502A5 [Poso et al, adapted from the publicly available
UCLA Chemistry 125 course]. The red and blue regions indicate
positions where it would be favourable, respectively unfavourable to
place a negative charge and the green/yellow regions where it would
be favourable/unfavourable to locate bulky groups
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hindrance or global effect such as desolvation may penalize
the binding of slightly larger groups. The modiﬁcation of a
branched group at another point around the scaffold may
however allow some of the previously excluded ligands to
become highly active. Indeed the mere addition of one
methyl group may result in a sudden tenfold leap in
potency, dramatically increasing ligand efﬁciency [166,
167]. It was demonstrated that these problems could be
circumvented using artiﬁcial intelligence methods (neural
network, support vector machine, etc.) that are insensitive
to the spatial alignment of the ligand scaffolds and that are
able to recognize particular combinations of properties
distributed around the scaffold of a set of active ligands
[168–170]. Artiﬁcial intelligence can be ubiquitously
implemented at various stages in the rational drug design
process to improve results that can be otherwise be more
uncertainly obtained with classical methods, especially
when assessing general properties that are the result of the
subtle combination of many different factors in relation to
others such as drug-likeness [171]. Various examples of
artiﬁcial intelligence applications and their limitations have
been published in JCAMD [172–175]. Notwithstanding the
utility of artiﬁcial intelligence, normal intelligence remains
useful in avoiding some of the all too common pitfalls in
the derivation and application of QSAR models [176].
We apologise to the many authors of methods that didn’t
make it into the above list (see ESM Table 1). Much good
work has been done that the editors certainlywouldn’t allow
us to include because citing all 1,200 articles published in
JCAMD in the ﬁrst 25 years would perhaps be a bit exces-
sive.WecouldhavementionedtheworkbyCheonprivilege
structures [177], or by Lotta et al. [178] on multivariate PLS
modelling of data sets. The recent work by Zhou et al. [179]
on the use of DFT calculation to accurately assess the
existence of intermolecular H-bonds in docking instances.
Sarmah et al’s[ 180] work on solvent effects also added
signiﬁcantly to the drug-designers toolbox, but the methods
described in these articles didn’t achieve hype status.
Where do we stand today?
The rapid increase in costs of developing and marketing
new medicines is not leaving the pharmaceutical industry
untouched. Recent years have seen a strong concentration
of activities in terms of mergers, buy-outs, and closures [7].
It may simply be, that a research-intensive industry like the
pharmaceutical industry does not lend itself to the type of
management that is common in consumer goods, fashion
and footwear. It seems a paradox, though, that the high
costs associated with drug design are caused by develop-
ment, marketing, and legal fees, but when it comes to cost-
reduction research departments are, euphemistically called,
consolidated. The past years have also seen a consolidation
of methods. JCAMD has published a large series of articles
in which multiple methods have been combined. [22, 128,
129, 181–185]. All these pipelines and otherwise combined
methods speed up the use of the existing tools, and allow
them to be applied to ever larger numbers of small mole-
cules in ever shorter times.
Actually, there is a new hype raging at the moment, and
it is called ‘translational science’. In the Wikipedia we ﬁnd
under translational research: ‘‘In the ﬁeld of medicine, for
example, it is used to translate the ﬁndings in basic
research more quickly and efﬁciently into medical practice
and, thus, meaningful health outcomes, whether those are
physical, mental, or social outcomes’’. In a sense, the
recent spate of articles on combining existing techniques
into more easily applicable super-tools ﬁt nicely to this
translational paradigm. It must be stated, though, that the
translation science hype is feeling stiff competition from
systems biology [186] and modelling pharmacokinetics and
pharmacodynamics [187]. Between the lines we read in
translational science that the pharmaceutical industry has
ﬁnally realized that our deep lack of understanding of all
aspects of the interaction of a medicine with a human being
is the main cause for luck still being the most determining
factor in the drug design process. Consequently, we see the
out-sourcing budgets of the large pharmaceutical industries
go up [188], and more and more fundamental research
performed in academia is ﬁnding its way to small and
medium size enterprises (SMEs) where it can be incorpo-
rated in their lean and mean research machines [9]. Big
pharma will at some time buy either their products or the
whole SMEs and convert validated targets and leads or
even Phase I products into new medicines.
This new paradigm will probably also be proven a hype
soon; only time can tell if translational research will rescue
the pharmaceutical industry, or that it will only better
illustrate what it all is that we don’t know yet. It remains a
fact that better understanding the underlying biology, better
treatment of all available data, and more intelligent com-
binations of data, information, and knowledge must be
beneﬁcial for the drug design process and thus, on the long
run, for all of us.
If the pharmaceutical industry wants academia more
involved in the drug design process they could themselves
make a giant ﬁrst step by making available all (or at least
very many) X-ray structures of protein–ligand complexes.
We estimate that the number of PDB [189, 190] ﬁles col-
lecting computer dust in the pharmaceutical industry is
considerably bigger than the 75,000 structures now in the
PDB. We have discussed this possibility with industrial
crystallographers who realized that they were sometimes
sitting on thousands of structure ﬁles for which secrecy was
J Comput Aided Mol Des (2012) 26:137–150 141
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even consider discussing with their management the
release of these data in fear of paranoia based rejection.
Another often heard rejection criterion is that they are a bit
ashamed for these data because often these ﬁles have not
been reﬁned any further than was needed to answer the
biological or pharmaceutical question at hand. We offer to
set up a database for these ﬁles, and we offer to re-reﬁne all
industrial structures of protein–ligand complexes. We will
then only release those coordinates to the wider public that
pass certain minimal validation criteria [191]. Obviously,
the ﬁles in this system will remain the property of the
depositors. If one day deposition of coordinate ﬁles into the
PDB becomes signiﬁcantly easier, we can consider
depositing all ﬁles in the PDB on behalf of the original
depositors. It might seem a bold promise to re-reﬁne per-
haps even 100,000 structures, but the PDB_REDO exper-
iment [192–196] shows that today this can be done. In
PDB_REDO we signiﬁcantly improved 85% of all pres-
ently available PDB ﬁles that were solved by X-ray. It
seems likely that structures that often have been minimally
reﬁned can be improved even easier. One can even
envisage that industries would like to look back at their
own coordinates after we went through the elaborate and
time consuming reﬁnement process for them; in manage-
ment speak that would be the ultimate win–win situation.
Dealing with data, information, and knowledge:
from hype to hope?
Despite massive efforts in the design of tools, databases,
robotic techniques, and management innovations, luck
seems to be at the basis of the discovery of most new
medicines [197]. The blockbuster Viagra is probably the
best illustration of the opportunism that we tend to call
serendipity [198].
In 1997, i.e., long before the ﬁrst GPCR structure
became available, Kuipers et al. [199] performed a massive
literature search for aryloxypropanolamines and similar
compounds binding to the serotonin 5HT-1a receptor and a
series of sequence similar amine receptors. A correlation
analysis [200] revealed that only one residue’s presence/
absence showed a perfect correlation with binding/non-
binding of a series of compounds. A mutational study
validated the hypothesis that this correlation indicated a
direct hydrogen bond between an alcohol group in the
aminergic ligand and asparagine 719 [201]. When the
structure of the human b2 adrenoceptor bound to carazolol
was solved by X-ray [PDBid 2RH1; 202], it showed indeed
two hydrogen bonds between Asn-719 and this similar
ligand (see Fig 4). By the way, in none of the GPCR
homology models available in 1999, did Asn-719 interact
with a ligand.
In another GPCR related project aimed at using as much
heterogeneous data as can possibly be combined, Oliveira
et al. [203] predicted the role of all ‘active site’ residues in
GPCRs, the pivotal role of Arg-340 [204], and even a
series of residue interactions involved in the activation
process, and the presence and location of helix VIII [205].
The recent ﬂurry of articles on GPCR Xray structures
[206–209], and especially the structure with a covalently
agonist-bound G protein [210] showed all these predictions
to be conceptually right.
These two GPCR-related examples make clear that there
is a lot to be gained from using experimental data. But these
examples also taught us how hard it is to actually get access
to those data. With the GPCRDB [211–213] we have started
a trend to make Molecular Class Speciﬁc Information
Systems (MCSIS). And a small company, Bio-Prodict
(www.bio-prodict.nl) recently caught on and is now making
MCSISes for a wide variety of commercially interesting
molecules [214–218]. Their systems (some of which are
freely accessible from their website) revolve around a
structure based, and thus very accurate multiple sequence
alignment (MSA) for a whole protein super-family. This
MSA then functions as the anchor on which to position all
kinds of data that can range from 3D structures to genome
Fig. 4 Ligand binding by Asn-
386. Left: (part of) the X-ray
structure of the b2 adrenoceptor
bound to an inverse agonist that
is ‘somewhat similar’ to
(S)-penbutolol. Right:
(S)-penbutolol binding of Asn-
386 in serotonin 5HT-1A
predicted long before the ﬁrst
GPCR structure data became
available
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stants, or from sequence correlation patterns to the predic-
tion of mutations that enhance the protein’s stability. As the
most powerful information tends to be carefully hidden in
the literature, an extensive set of literature-mining scripts
aids with the extraction of, for example, mutation infor-
mation. In fact, it was shown that the suite of mutation data
extracting scripts reaches a much better coverage than can
be obtained by human experts [214–218].
A recent development that will aid the drug hunters of
the future is the Utopia PDF reader [213, 219]. Vroling et al.
[213] showed how this programmable PDF reader could be
used to directly couple data in articles on GPCRs to the
GPCRDB. This intelligent hyperlinking has a series of
beneﬁts. First, the residue numbering problem gets solved
because the reader can ask the GPCRDB for the position in
the GPCR MSA of any residue mentioned in the article, and
it can even modify or correct the sequence numbers in the
article if needed. Much good GPCR mutation data was
published in the pre-GPCR-structure era that ended with the
opsin structure article [220], and often these data were
misinterpreted because of the poor quality of the available
homology models [221]. The Utopia-GPCR PDF reader can
correct those interpretations thereby salvaging old, high
quality experimental data for future use. Figure 5 shows an
image from an old mutation study [222] in which the
authors describe several ground-breaking mutations in the
guinea pig histamine H1 receptor, building and validating a
homology model using these data, and arguing, for exam-
ple, that residue Trp161 plays an important role in receptor-
ligand binding. This assumption was based on the effect of
the mutation on receptor function, leading to a model in
which Trp161 was modelled in the ligand-binding site. By
contrast, the GPCRDB generated annotation listed in the
sidebar of the reader indicates that this residue, located in
TM IV, points towards the membrane and possibly interacts
with cholesterol. This is a completely different situation
from that proposed by the authors. Looking at the model
provided by the GPCRDB, based on the latest crystal
structures, it can be seen that a direct role of Trp161 in
receptor-ligand binding is highly unlikely.
Folkerstma et al. (2005) analyzed nearly 100 nuclear
receptor (NR) ligand binding domains. Combined with
manually curated multiple sequence alignments, key posi-
tions in the ligand binding pocket were identiﬁed that had
speciﬁc interactions with functionally diverse compounds.
For example, residues at position 26 in Fig. 6 were shown
to only have interactions with antagonists. This analysis
required a substantial amount of work: categorizing struc-
tures and compounds, creating multiple sequence align-
ments, analyzing ligand contacts, and transferring the
results into a homogeneous residue numbering scheme (the
so-called 3D numbers). With the 3DM information system
[223; see the help movie], these analyses can today be
performed in a matter of minutes [215, 217, 224].
More than 100 articles were found that discuss the
effects of mutating this residue on the ligand binding of the
receptor. In all these articles this same residue has 14
different residue numbers ranging from 52 to 709. The use
of a common 3D numbering scheme enables transfer of
heterogeneous information between protein family mem-
bers. Figure 7 shows 40 antagonists in red and 70 agonists
in blue. In this example, a hundred articles had to be ‘read’
to extract all available mutation information for this single
position mutated in 22 different receptor—species combi-
nations. That these 100 articles had to be found among
Fig. 5 Left, one page from the Histamine H1 article by Wieland et al.
[222] in which Trp161 is suggested to interact with the ligand while
the PDF reader sidebar shows today’s interpretation that this
tryptophan is facing outwards towards the lipid or a dimer partner.
The original picture of the modelled active site is shown enlarged in
the middle panel while the right hand side ﬁgure is a plot of the
GPCRDB-derived model of this receptor. The GPCRDB does not
(yet) dock ligands, so the ligand is represented by a hand-added gray
ball
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whole different story in itself.
If, one day, all structures of NR-ligand complexes that
now are scattered over inaccessible industrial hard disks
could be concentrated in one system, then we could con-
sider asking much more elaborate questions. We could
consider correlating aspects of ligands with protein atom
characteristics, or we could analyse if residues not
contacting the ligand have an inﬂuence on binding or
activation, etcetera.
It is not only important to get as much information as
possible stored in systems amenable to scrutiny, but it is
also important to realize that for every one bioinformati-
cian or drug hunter there are one hundred scientists who do
not use molecular software regularly. Project Hope aims to
predict the molecular phenotype of point mutations that
were shown causally related to human disease states [225].
This system attempts in all stages of user interaction to
cater for human geneticists who typically do not use
molecular software at all. Hope only asks the user to cut-n-
paste the sequence, and click the residue mutated and the
mutation residue type. It then builds a homology model if
needed, calls dozens of servers and services in seven
countries, combines all possible information and writes a
ﬁnal report that can be directly used in publications, but,
more importantly, that is written without using any bioin-
formatics jargon and even has a build-in dictionary that
explains terms such as ‘active site’, ‘salt-bridge’, or ‘tor-
sion angle’ in human genetics understandable terms. Hope
thus is the ultimate translation machine because in doing
translational research it even translates between the
researchers.
We believe that the recent spate of consolidations in the
pharmaceutical industry is not a problem but an opportu-
nity. Mankind needs medicines, and now that pushing ones
luck is slowly becoming a less successful technique, only
research can ﬁnd them. This research can progress rapidly
if the thousands and thousands of X-ray structures of pro-
tein–ligand complexes would ﬁnd their way from hard-
disks behind pharmaceutical industry ﬁrewalls to the public
domain. Drug design research in the next 25 years will
revolve around ever broader collaborations, ever more
holistic understanding of the drug—human interactions,
Fig. 6 Bargraph showing the
number of ligand contacts per
residue extracted from 776
nuclear receptor ligand binding
domain structures plotted as
function of their 3D numbers.
The blue bars represent the
number of contacts with
agonistic compounds. The red
bars indicate the number of
contacts with antagonistic
compounds. The residue with
3D number 26 is only bound to
antagonistic compounds
Fig. 7 Cartoon representation of two superposed representative NR
structures (one bound to an agonist; one bound to an antagonist).
These two structures, obviously, differ most in the location of Helix
12. The blue ligands are agonists; the red ones are antagonists. The
ligands were placed in the same orientation as found in their native
PDB ﬁle. All PDB ﬁles were superposed on the representative NR
structures. Residue 26, for which the antagonist interaction had been
mentioned in the literature, is shown in yellow, as is residue for which
Fig. 6 also indicates antagonist interactions, albeit with less antag-
onists than residue 26. This role of residue 29 might represent a novel
ﬁnding. Figure made with the 3DM-plugin for the YASARA—
WHAT IF suite
144 J Comput Aided Mol Des (2012) 26:137–150
123and ever better use of the available data, information, and
knowledge.
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